Prasugrel
Prasugrel is a pharmaceutical drug with 104 clinical trials. Currently 3 active trials ongoing. Historical success rate of 92.1%.
Success Metrics
Based on 82 completed trials
Phase Distribution
Phase Distribution
9
Early Stage
12
Mid Stage
76
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
90.1%
82 of 91 finished
9.9%
9 ended early
3
trials recruiting
104
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months
Use and Costs of P2Y12 Inhibitors After Acute Myocardial Infarction
Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.
Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)
A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects
Clinical Trials (104)
Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months
Use and Costs of P2Y12 Inhibitors After Acute Myocardial Infarction
Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.
Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)
A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects
The Elderly ACS II Trial
Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI
Clopidogrel Monotherapy in Patients With High Bleeding Risk
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome
Effects of Ticagrelor Versus Prasugrel on Coronary Microcirculation in Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the PROtecting MICROcirculation During Coronary Angioplasty (PROMICRO)-3 Randomised Study
Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial Aneurysm
Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study
Platelet Aggregation and Adenosine Levels Among Patients Taking Ticagrelor or Prasugrel
Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)
Prasugrel/Clopidogrel Maintenance Dose Washout Study
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study
A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:
Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor
The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 104